Antisense therapy for cancer (Q36133133)

12 August 2017

1 reference

title

Antisense therapy for cancer. (English)

1 reference

12 August 2017

Martin E Gleave

1

1 reference

12 August 2017

Brett P Monia

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

12 August 2017

published in

Nature Reviews Cancer

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

6

1 reference

12 August 2017

page(s)

468-479

1 reference

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

12 August 2017

cites work

1 reference

Antisense therapy: current status in prostate cancer and other malignancies

21 January 2018

1 reference

Antisense oligonucleotide-based therapeutics for cancer

21 January 2018

1 reference

Molecular mechanisms of antisense drugs: RNase H.

21 January 2018

1 reference

Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs

21 January 2018

1 reference

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

21 January 2018

1 reference

RNAi-mediated pathways in the nucleus

21 January 2018

1 reference

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

21 January 2018

1 reference

Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo

21 January 2018

1 reference

Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma

21 January 2018

1 reference

Bcl-2 and the regulation of programmed cell death

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow

21 January 2018

1 reference

Bcl-2 antisense therapy in B-cell malignancies

21 January 2018

1 reference

Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment.

21 January 2018

1 reference

Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.

21 January 2018

1 reference

Regulation of protein kinase C.

21 January 2018

1 reference

12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha

21 January 2018

1 reference

MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype

21 January 2018

1 reference

Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta

21 January 2018

1 reference

Protein kinase C inhibitors

21 January 2018

1 reference

Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells

21 January 2018

1 reference

Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells

21 January 2018

1 reference

Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides

21 January 2018

1 reference

Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha

21 January 2018

1 reference

Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer

21 January 2018

1 reference

Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB

21 January 2018

1 reference

Overexpression of clusterin in human breast carcinoma

21 January 2018

1 reference

Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas.

21 January 2018

1 reference

Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

21 January 2018

1 reference

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy

21 January 2018

1 reference

Clusterin is a secreted mammalian chaperone

21 January 2018

1 reference

Stress-induced transcription of the clusterin/apoJ gene.

21 January 2018

1 reference

Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin

21 January 2018

1 reference

Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress

21 January 2018

1 reference

Control of apoptosis and mitotic spindle checkpoint by survivin

21 January 2018

1 reference

Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice

21 January 2018

1 reference

Pathways of apoptotic and non-apoptotic death in tumour cells

21 January 2018

1 reference

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

21 January 2018

1 reference

Survivin, versatile modulation of cell division and apoptosis in cancer

21 January 2018

1 reference

Pleiotropic cell-division defects and apoptosis induced by interference with survivin function

21 January 2018

1 reference

Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth

21 January 2018

1 reference

X-linked IAP is a direct inhibitor of cell-death proteases

21 January 2018

1 reference

The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites

21 January 2018

1 reference

IAP proteins: blocking the road to death's door

21 January 2018

1 reference

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein

21 January 2018

1 reference

The STATs of cancer--new molecular targets come of age

21 January 2018

1 reference

A critical role for Stat3 signaling in immune tolerance

21 January 2018

1 reference

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

21 January 2018

1 reference

STAT proteins: novel molecular targets for cancer drug discovery

21 January 2018

1 reference

HSP27 and HSP70: potentially oncogenic apoptosis inhibitors

21 January 2018

1 reference

On the role of Hsp27 in regulating apoptosis

21 January 2018

1 reference

Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review

21 January 2018

1 reference

Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity

21 January 2018

1 reference

Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways

21 January 2018

1 reference

Do heat shock proteins have a role in breast cancer?

21 January 2018

1 reference

Identification of differentially expressed proteins in human glioblastoma cell lines and tumors

21 January 2018

1 reference

Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo

21 January 2018

1 reference

Hsp27 as a negative regulator of cytochrome C release

21 January 2018

1 reference

A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures

21 January 2018

1 reference

Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices

21 January 2018

1 reference

Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice

21 January 2018

1 reference

A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides

21 January 2018

1 reference

Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species

21 January 2018

1 reference

LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA.

21 January 2018

1 reference

Insulin-like growth factors and neoplasia.

21 January 2018

1 reference

MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain

21 January 2018

1 reference

Functional analysis of the human MCL-1 gene

21 January 2018

1 reference

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

21 January 2018

1 reference

MCL-1 expression in B-cell non-Hodgkin's lymphomas

21 January 2018

1 reference

Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide

21 January 2018

1 reference

Bcl-xL antisense oligonucleotides radiosensitise colon cancer cells

21 January 2018

1 reference

Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer.

21 January 2018

1 reference

Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms

21 January 2018

1 reference

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

21 January 2018

1 reference

Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2.

21 January 2018

1 reference

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

21 January 2018

1 reference

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

21 January 2018

1 reference

Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins

21 January 2018

1 reference

Bcl-XL is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy

21 January 2018

1 reference

bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells

21 January 2018

1 reference

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

31 March 2020

1 reference

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

31 March 2020

1 reference

Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells

31 March 2020

1 reference

Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model

31 March 2020

1 reference

Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model

31 March 2020

1 reference

Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence

31 March 2020

1 reference

Androgen-repressed messages in the rat ventral prostate

31 March 2020

1 reference

Antisense clusterin oligodeoxynucleotides increase the response ofHER-2 gene amplified breast cancer cells to Trastuzumab

31 March 2020

1 reference

The inhibitors of apoptosis (IAPs) and their emerging role in cancer

31 March 2020

1 reference

Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma

31 March 2020

1 reference

Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis

31 March 2020

1 reference

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer

31 March 2020

1 reference

Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy

31 March 2020

1 reference

HSP27 inhibits cytochrome c-dependent activation of procaspase-9.

31 March 2020

1 reference

Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway

31 March 2020

1 reference

Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers

31 March 2020

1 reference

Expression of apoptotic regulators and their significance in cervical cancer

31 March 2020

1 reference

Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks

31 March 2020

1 reference

Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies

31 March 2020

1 reference

Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC1631

1 reference

Dimensions Publication ID

12 August 2017

1041122269

0 references

1 reference